Bonus BioGroup has currently ongoing clinical trials for the evaluation of BonoFill^TM bone graft safety and efficacy in two indications: Orthopedic indication and Maxillofacial indication.

In August, 2017 Bonus BioGroup announced the first tissue-engineered human bone graft transplantation into the patient’s bone defects in the lower arm bones, as part of a clinical trial for the reconstruction of extensive critical bone loss in bones of the extremities.

Following recruitment, patients undergo tests for evaluation of their suitability for participation in the trial. Once eligibility is confirmed, a liposuction is scheduled, after which within approximately two weeks of the fat tissue sample harvesting, the participant will undergo a grafting procedure with a personalized, injectable, viable bone graft into the deficient site in need of bone repair.